Article
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Current opinion in oncology - 1 Mar 2010
Rosell Rafael, Viteri Santiago, Molina Miguel Angel, Benlloch Susana, Taron Miquel
Abstract excerpt
PURPOSE OF REVIEW: Classic activating mutations in the form of deletions in exon 19 or a missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) predict dramatic responses to EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib. We review he...
Topics
- Antineoplastic Agents
- Asian People
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Quinazolines